SCHEMBL2033159

SCHEMBL2033159

C=Cc1ccc(C=Cc2cc(C=Cc3cc(C(C)(C)C)cc(C(C)(C)C)c3)cc(C=Cc3cc(C(C)(C)C)cc(C(C)(C)C)c3)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.42
TDP1 Q9NUW8 2/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
MAPT P10636 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
BLM P54132 1/20 0.41
CASP7 P55210 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PTGS2 P35354 4/20 0.40
PTGS1 P23219 3/20 0.40
CYP1A2 P05177 2/20 0.39
APP P05067 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRB2 P47870 1/20 0.35
NFE2L2 Q16236 1/20 0.35
AHR P35869 2/20 0.34
TTR P02766 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6876801 0.98 ALDH1A1 (0.44) ALDH1A1TDP1TP53CYP3A4MAPT
SCHEMBL7759021 0.98 ALDH1A1 (0.44) ALDH1A1TDP1TP53CYP3A4MAPT
SCHEMBL6571930 0.90 GABRA1 (0.39) ALDH1A1TDP1TP53CYP3A4MAPT
SCHEMBL2427389 0.90 GABRA1 (0.39) ALDH1A1TDP1TP53CYP3A4MAPT
SCHEMBL6573320 0.90 TP53 (0.46) TDP1TP53CYP3A4MAPTALOX15
SCHEMBL6573426 0.90 TP53 (0.46) TDP1TP53CYP3A4MAPTALOX15
SCHEMBL6573201 0.90 TP53 (0.46) TDP1TP53CYP3A4MAPTALOX15
SCHEMBL6876844 0.84 CYP1A2 (0.53) ALDH1A1MAPTMAPK1SMN1; SMN2CYP1A2
SCHEMBL6884409 0.84 CYP1A2 (0.53) ALDH1A1MAPTMAPK1SMN1; SMN2CYP1A2
SCHEMBL2029883 0.82 PTGS1 (0.58) TDP1TP53CYP3A4MAPTALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960557-B2 Asymmetric dendrimers ISIS INNOVATION LIMITED (GB) 2011-06-14 US disclosed
US-20090326238-A1 ASYMMETRIC DENDRIMERS ISIS INNOVATION LIMITED (GB) 2009-12-31 US disclosed
US-7537842-B2 Asymmetric dendrimers ISIS INNOVATION LIMITED (GB) 2009-05-26 US disclosed
EP-1373431-B1 ASYMMETRIC DENDRIMERS ISIS INNOVATION (GB) 2006-10-18 EP disclosed
US-20040110029-A1 Asymmetric dendrimers CAMBRIDGE DISPLAY TECHNOLOGY LIMITED (GB) 2004-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326238-A1 ASYMMETRIC DENDRIMERS DNM2, DYNLL2, DNM1 ALDH1A1 1358/4885TDP1 2365/4885TP53 4264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.